The Best and Brightest Minds and Ideas at Work

The cornerstone of our research and development is MetaProteomics, LLC, our wholly-owned biotechnology subsidiary. Established in 2002, MetaProteomics houses state-of-the-art technology and is home to one of the largest and most diverse scientific staffs in the natural products industry.

Clinical Focus Areas

Our MetaProteomics team—including top notch phytochemists, biochemists, MDs, RNs, registered dietitians, nutritionists, and other highly respected researchers and clinicians—shares a collective sense of urgency when it comes to finding the most effective natural ingredients/ingredient combinations to be developed into Metagenics' medical food and nutraceutical formulas. Their work has culminated in a line of high quality, science based formulas that effectively address:

• Cardiovascular health
• Blood sugar concerns
• Gastrointestinal health
• Immune health
• Joint issues
• Women's health
• Men's health
• Musculoskeletal health
• Neurological health
• Stress management
• Detoxification
• Foundation Nutrition

So far, MetaProteomics discoveries have resulted in more than 230 domestic and international patents awarded and pending—a feat that no other company in our industry niche can boast.

A Unique Product Development Model

The MetaProteomics product development platform is called the ExpresSyn® Process. This proprietary process—designed to ensure the effectiveness and predicted safety of our nutritional formulas—combines the best of medical, biotechnology, and pharmacological discovery techniques and Metagenics' in-depth knowledge of natural ingredients.

The ExpresSyn Process involves the following processes:

• Ingredient Discovery. The health-supporting properties of hundreds of natural compounds and compound mixtures derived from foods, spices, and herbs with a long history of safe use are identified via in vitro enzyme assays, cell culture models, and other forms of testing.
• Proof of Concept. Additional testing is conducted to provide preliminary confirmation of the desired clinical target. The formulas with acceptable safety profiles at therapeutic doses are evaluated for bioavailability and metabolism in humans.
• Formula development. A source-safe pipeline of natural ingredients is identified, then products are formulated in the form (tablet, soft gel, or bar) that's most appropriate for the therapeutic target.
• Clinical experience. The new formula is evaluated for effectiveness using observational studies and random controlled studies.

A Promising New Therapeutic Agent: Selective Kinase Response Modulators (SKRMs)

A key MetaProteomics discovery is the existence and mechanism of highly specialized bioactive molecules known as selective kinase response modulators, or SKRMs. Our research identified SKRMs derived from plant-based compounds, as having the ability to modulate specific cell signaling pathways, which may play a role in chronic illness. This mechanism of action is exciting in that it's different from any other class of therapeutics.

SKRMs derived from hops (Humulus lupulus L.), acacia (Acacia nilotica), and other phytocompounds have been successfully incorporated into Metagenics formulas to address:

• Chronic inflammation
• Minor pain
• Insulin resistance
• Metabolic syndrome
• Bone remodeling

Research on further therapeutic applications of SKRM technology is underway.

For more information on our exciting scientific discoveries, please Contact Us.